Conditions: Diabetes Mellitus, Type 2
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 241
Healthy volunteers: no

Brief summary:
The objective of the current study is to investigate the efficacy, safety and tolerability of linagliptin (5 mg / once daily) compared to placebo given for 24 weeks as add-on therapy to stable treatment in elderly patients with T2DM with insufficient glycaemic control

Detailed description:

Arms:
arm 1: patients receive linagliptin 5 mg tablets once daily arm 2: patients receive placebo tablets matching linagliptin 5 mg once daily

Interventions: intervention 1: linagliptin intervention 2: placebo
Intervention descriptions: intervention 1: patients receive linagliptin 5 mg tablets once daily intervention 2: patients receive placebo matching linagliptin 5 mg once daily

Protocol document: